Introduction
Thyroid function testing has provided the major endocrine workload in laboratories for many years. This workload has been considerably augmented by the introduction in some laboratories over the last 5 years of regional screening programmes for the early detection of congenital hypothyroidism. The pressure on laboratories to provide efficient thyroid function testing has been partly responsible for the enormous technological developments that have been introduced recently through the efforts of research laboratories and commercial manufacturers. Sadly, however, there have been occasions where diagnostic accuracy has been sacrificed in favour of technical convenience, for example, in the use of certain free hormone assays.' In this article we shall review recent advances in the measurement of thyrotrophin (TSH) and try to assess the potential of the new generation of TSH assays in improving the diagnostic accuracy of thyroid function testing.
Role of TSH in thyroid function
The secretion of thyroid hormones is dependent on stimulation by TSH synthesised, and secreted by, thyrotroph cells of the anterior pituitary. While this in turn is regulated by the hypothalamic peptide TRH, the most important control of thyrotroph activity is provided by the circulating levels of T3 and T4. It is well recognised that inadequate production of these hormones results in a secondary elevation of circulating TSH which in itself is used to confirm a diagnosis of hypothyroidism. In contrast, an increase in thyroid hormone secretion results in inhibition of TSH production, This paper was prepared at the invitation of the Clinical Laboratory Investigation Working Party of the Scientific Committee of the Association of Clinical Biochemists, but does not necessarily reflect their views. though attempts to utilise this suppression of thyrotroph secretion as a means of diagnosing hyperthyroidism have been hampered by the relative insensitivity of TSH immunoassays. The usefulness of TSH measurement in patients with suspected hyperthyroidism has been in assessing responsiveness to a bolus injection of TRH. An absent or impaired response to TRH may indicate hyperthyroidism; a normal response excludes such a diagnosis.
Problems of TSH measurement
A number of factors have combined to make circulating TSH one of the more difficult analytes for the immunoassay laboratory. Poor specificity has been a common problem since antisera raised to TSH will frequently crossreact with other pituitary glycoprotein hormones as well as with chorionic gonadotrophin. The consequences of this cross-reactivity are manifested as apparently raised TSH levels in post-menopausal and pregnant women. The prevalence of thyroid disease in postmenopausal women increases the potential for misdiagnosis. In addition, the alterations in thyroid hormone levels during pregnancy may add to the difficulty of assessing thyroid status.
Another problem has been the limited availability of good quality reagents including purified TSH and high avidity antibodies. Though this is now less of a problem, variability in reagent quality has in the past compromised the performance of conventional radioimmunoassay (RIA) systems.
A further constraint is imposed by the immunoassay system itself. It has been argued on theoretical grounds that the sensitivity of a conventional RIA increases as the reagent concentration tends towards zero." In the case of TSH, this has been demonstrated by the elegant studies of Wide and Dahlberg' who highlighted the diagnostic potential of a conventiorral RIA optimised to yield maximum sensitivity. Though the assay required a reaction time of 7 days, it offered good discrimination between normal and hyperthyroid basal TSH concentrations which in turn could be used as predictive indicators of TRH responsiveness-observations which have been confirmed recently using one of the newer assay systems discussed below. 4 However, the care and patience required for this RIA procedure have precluded its use in routine investigation and it has been the introduction of the new technology which has provided high sensitivity in a user-friendly form.
Assay improvements
The most significant development in TSH measurement has been the introduction of immunoradiometric assay (IRMA) technology. As long ago as 1968, Miles and Hales 5 pointed out the advantages of procedures that use excess labelled antibodies when compared with conventional competitive assay methods. They argued that reagent excess systems were kinetically more favourable than limited antibody systems, and created the potential for faster and more sensitive assay procedures. Corning Medical were the first to exploit this method for TSH measurement using a procedure based on reaction of sample with 1251-labelled antibody followed by reaction of the complex with antibody covalently linked to porous glass. The total reaction could be carried out within 2 h and the immune complex removed by centrifugation prior to counting.
The main problems with these techniques have been the requirement for large volumes of antiserum and the need to purify antibody from polyclonal antisera before labelling, which in turn requires the use of relatively large quantities of solid-phase antigen. A further difficulty has been the need for careful screening of these antibodies to minimise cross-reactivity with other glycoprotein hormones.
These problems have been overcome by the use of monoclonal antibodies to TSH, which can be produced in large quantities in a high degree of purity and which offer the selectivity necessary to eliminate potential cross-reactions. The available assays based on monoclonal antibodies share a common overall format in adopting a two-site assay procedure, that is reaction of TSH with solid phase antibody and 1251-labelled antibody, but differ in details of the separation procedure; these differences affect individual assay performance.
Hybritech, one of the first companies to market assay kits based on monoclonal antibody technology, rely on the use of antibodycoated beads which are reacted first with sample and then with labelled antibody. Though convenient to use, the reaction kinetics of bead systems are unfavourable and do not meet the performance potential of labelled antibody systems, particularly with regard to sensitivity. This is not true in the case of the kits marketed by Boots/Celltech and Serono which both use particulate preparations of solid phase antibodies. Both kits involve two reactions. The Boots/Celltech method is similar to that of Corning Medical in that sample is reacted first with labelled antibody and then with solid phase antibody. The difference is that both antibodies are monoclonal. Also the solid phase is Sepharose beads which are separated after the second reaction by sedimentation through layered sucrose solution. The Serono method involves simultaneous reaction of sample with three monoclonal antibodies-two labelled with 125 1 and the third with fluorescein isothiocyanate (FITC). Separation is achieved by addition of antibodies to FITC linked to magnetisable particles. This method combines the advantages of rapid reaction kinetics with a highly convenient separation procedure.
It is interesting that the factor limiting the sensitivity of these optimised reagent excess assays is actually the detection limit of the label; this contrasts with RIA in which antibody avidity is ultimately the limiting factor.f One attractive feature of labelled antibody methods is the notion of improving detection limits by increasing the specific activity of the labelled antibody. In practice, assay performance is compromised when more than one atom of 125 1 per molecule of antibody is incorporated, presumably because of radiolytic damage." It is only through the use of non-isotopic labels that it has been possible to demonstrate the importance of specific activity in determining immunometric assay sensitivity. With a chemiluminescent acridinium salt as a label it has been shown that a ten-fold increase in specific activity can produce a five-fold improvement in the sensitivity of an immunochemiluminometric assay (ICMA) of u.-fetoprotem." Application of this technology to TSH measurement has led to the development of an assay with a sensitivity better by a factor of 10 than the corresponding IRMA methods," even when identical reagents are employed." It remains to be seen if this sensitivity can be matched or bettered with alternative non-isotopic methods such as enzyme amplified immunometric or time-resolved f1uorimetric assays.
Clinical significance of high sensitivity assays
The full potential of these new approaches to TSH measurement in terms of clinical value remains to be assessed. There have been several recent reports that these high sensitivity methods offer the possibility of using TSH as a first-line test of thyroid function which offers good discrimination between hyperthyroid patients and normal subjects, in addition to its established role in confirming hypothyroidisrn.": &-12 To put these claims into perspective, however, it is necessary to evaluate the methods available in terms of routine performance.
Analytical performance data for a group of TSH assays are compared in Table 1 . For comparative purposes, the working range has been defined as the dose limits where the coefficient of variation in the dose (CV) is 10% or less. Values outside these performance limits may still be useful, though of course less confidence can be placed in them. It is important to realise that the quoted sensitivity may be irrelevant to the application of the assay. These values are frequently based on the 95% confidence limits of 20 replicate estimations. Since patient samples are not assayed in replicates of 20 the significance of such a figure is questionable. Here, the precision profile based on duplicate estimates is more helpful in interpreting low analyte values. IJ
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The use of 0·08 mUlL asa cut-off for the Boots/Celltech TSH assay is misleading since the CV at that dose is of the order of 25%. It is hardly surprising therefore that a significant proportion of normal values (2'3%) fall within the hyperthyroid range. In contrast the reference range identified using the Serono kit has a lower limit of 0·5 mUlL though hyperthyroid TSH values up to 0·8 mUlL have been observed. The problem of overlap was carefully analysed by Wide and Dahlberg' who demonstrated the effect of increasing precision on discrimination of hyperthyroid from normal TSH levels. In our own studies with the ICMA H we find no overlap. The lower limit of normal is 0·4 mUlL and the highest level in 90 hyperthyroid patients studied was 0·03 mUlL. The only values falling between these limits were found in a proportion of euthyroid patients with multinodular goitres. Such levels may indicate a subclinical hyperthyroid state.
The new methods are not without problems. Standardisation has not been easy particularly in the requirement for serum diluent which is genuinely 'hormone-free'. Apart from taxing the patience of all but the most devoted laboratory worker, the tantalisingly low count rates of the Boots/Celltech IRMA (less than 100 cpm at zero antigen) introduce problems of error assessment at low hormone concentrations. In the case of the non-isotopic methods there has been a requirement for new instrumentation which may be unfamiliar to the clinical chemistry laboratory, though this is offset by the high sensitivity and stability of performance. The challenge is now with the laboratory. It is already apparent that as a first-line test TSH is more efficient than T4, in that misclassification of normal, hyperthyroid and hypothyroid patients is unlikely. This is not intended to imply that it becomes the only test of thyroid function. A basal TSH together with a clinical history may be used as a basis for further investigation such as measurement of thyroid hormones or, if appropriate, free thyroid hormones.
Other problems relating to thyroid function need to be studied. It will be important to establish, for example, whether basal TSH measurement will obviate the need to perform TRH tests in all those cases where they are presently employed. In view of the circadian rhythm in TSH secretion!" it will be important to standardise the time of sampling, particularly in establishing reference ranges." A further area of importance relates to the monitoring of therapy. Preliminary studies suggest that the assessment of response to treatment in both hypothyroid and hyperthyroid patients can be carried out effectively with a sensitive TSH assay.
Another problem which may be resolved with these tests is that presented by the sick euthyroid syndrome, where assessment of patients on the basis of thyroid hormone assays is not always easy. It should be possible, however, by TSH measurement to avoid the problems generated by the presence of abnormal binding proteins or drugs which affect the interaction of the thyroid hormones with those proteins. One potentially exciting area which warrants further investigation is that of the circadian rhythm of TSH secretion. In addition to detection of early alterations in thyroid function, it may also prove decisive in the diagnosis of thyroid abnormalities which are secondary to pituitary dysfunction.
In these cost-conscious days it is desirable that any new test should be cost-effective as well as improving diagnostic efficiency. At present it is difficult to assess the long-term cost-effectiveness of these new procedures. While it is likely that sensitive TSH assays will reduce the overall numbers of tests carried out in thyroid function assessment, commercial assays are not cheap and if they replace inhouse assay procedures this could result in a high price being paid for the improved diagnostic efficiency. However, the almost universal subscription to relatively expensive free hormone assays that has occurred recently suggests that laboratories may obtain their improved efficiency without too great a financial burden. In view of the fact that the endocrine laboratory may have little control over the requests for thyroid function tests, education of those who wish to investigate thyroid function will be important in establishing the effectiveness of these new laboratory procedures. This will only be possible when these new assays have been applied to the wide variety of clinical situations in which the laboratory is asked to assess thyroid function.
